Category: Drug Discovery

  • AI specialist Charm Therapeutics launches with $50m Series A

    The UK’s fertile environment for biotechs specialising in artificial intelligence has generated a new player – Charm Therapeutics – which came out of stealth mode this morning with a $50 million first-round financing. The London-based startup has been founded by David Baker, head of the Institute of Protein Design at the University of Washington in […]

  • AI specialist Insilico raises $60m as more projects head to clinic

    Insilico Medicine has raised $60 million in fourth-round financing that will help to fund the advancement of more drugs towards the clinical testing stage. The Hong Kong-based startup – one of an emerging crop of companies which are using artificial intelligence platforms to discover and design new therapeutic compounds – took its first drug into […]

  • New Flagship Pioneering startup expands the protein universe to fuel drug discovery

    ProFound Therapeutics emerged from stealth with technology that it claims has discovered tens of thousands of previously undiscovered proteins—many of them promising new drug targets. The Flagship Pioneering-founded startup is backed by $75 million to support its drug R&D along with plans to partner with large pharmaceutical companies.

  • Buried Under Dirt or Under Debt: Can Patients Survive the Struggle of Getting Care?

    Srulik Dvorsky, TailorMed CEO and Founder New patients at a cancer center in Michigan receive a 79-page handbook when their treatments commence. The handbook includes needed advice on what to eat and the side effects of chemotherapy drugs. One double-sided page features information about how to navigate the financial aspects of cancer treatment, including who […]

  • Character Biosciences Raises $18M to Expand Precision Medicine Platform for Diseases of Aging

    What You Should Know: – Character Biosciences (“Character”), a precision medicine platform for diseases of aging raises $18M in a new funding round led by Innovation Endeavors, alongside leading life sciences investors Section 32 and Catalio Capital Management. Formerly known as Clover Therapeutics, the company’s data-driven approach integrates genomics, deep phenotyping and machine learning for […]

  • AstraZeneca extends oncology partnership with Proteros

    AstraZeneca has boosted its research capacity by extending its oncology partnership with Proteros biostructures. German pharma firm Proteros specialises in structure-based drug discovery powered by a cutting-edge discovery engine that can unlock complex and technically challenging disease-relevant targets. Proteros’s expertise and tools speed up the research process, particularly at the initial drug discovery and development […]

  • Novo Nordisk forges close ties with biotech VC Flagship

    Danish drugmaker Novo Nordisk has traditionally generated its pipeline mainly from internal R&D, but a new alliance with venture capital firm Flagship Pioneering signals another departure from that strategy. The partnership with Flagship will bring Novo Nordisk into closer contact with the VC’s portfolio of 41 biotech companies, with the aim of creating a portfolio […]

  • How patient-on-a-chip tech could be the future of drug discovery

    Testing drug compounds on a chip designed to mimic human organs sounds closer to science fiction than reality, yet the technology already exists and is already being put to use. Ben Hargreaves discovers how the technology could provide more accurate safety predictions and even discover new treatments. The limits of animal models in drug discovery […]

  • Google, Sanofi back UK biotech OMass’ $100m second round

    OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development. The Oxford-based company said the financing, led by venture capital arms of Google and Sanofi as well as Northpond Ventures, will be used to bring […]

  • Ligand Pharma turns to a SPAC to take antibody biz public, raise up to $266M

    OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public through a SPAC merger that will infuse the business with up to $266 million. The deal comes as traditional IPOs have mostly ground to a halt due to uncertain market conditions, but Ligand is making a longer-term bet on growing demand for antibody […]

  • GSK partners LifeMine on fungi-derived medicines

    GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. There’s a rich history of finding useful medicines from fungi, from the antibiotic penicillin to immune suppressant cyclosporine and cholesterol drug lovastatin. […]

  • NVIDIA Launches AI Computing Platform for Medical Devices

    What You Should Know: – NVIDIA today introduced Clara Holoscan MGX, a platform for the medical device industry to develop and deploy real-time AI applications at the edge, specifically designed to meet required regulatory standards. – Clara Holoscan MGX expands the Clara Holoscan platform to provide an all-in-one, medical-grade reference architecture, as well as long-term […]

  • BMS buys into Volastra’s cancer expertise with $1.1bn alliance

    Bristol-Myers Squibb is the first big pharma to strike a deal with Volastra Therapeutics, a start-up that has developed a drug discovery platform based on chromosomal instability (CIN), a common but under-investigated feature of solid tumours. BMS is paying $30 million into the collaboration upfront, with a total deal value of $1.1 billion, for programmes […]

  • Benchling Acquires Overwatch Research to Accelerate Breakthroughs for Biopharma Companies

    What You Should Know: – Today, R&D Cloud pioneer Benchling announced it has acquired Overwatch Research to accelerate in vivo research. – The acquisition will create the industry’s first comprehensive, cloud-native in vivo solution – a critical component of drug discovery and development – drastically accelerating the time it takes biopharma companies to bring products […]

  • Sema4, BioSymetrics Partner to Advance Data-Driven Drug Discovery

    What You Should Know: – Today, Sema4, a leader in AI-driven clinical data intelligence, announced that they have partnered with BioSymetrics, to accelerate the advancement of drug discovery and new treatments for patients and pharmaceutical companies. – Together the two will leverage Sema4’s Centrellis®, one of the largest and fastest-growing integrated health information platforms that includes approximately […]

  • Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety

    German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process. Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine […]

  • BenchSci raises $50m to grow AI-powered R&D platform

    Canadian firm BenchSci has secured around $50 million in third-round financing that will be used to speed up the adoption of its artificial intelligence-powered platform for biomedical research internationally. The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving […]

  • SMi’s 3rd Annual AI in Drug Discovery Conference

    Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare SMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference, taking place on the 14th and 15th March 2022 in London, UK. Chaired by: Darren Green, Director of Computational Chemistry, GSK Sponsored by: Optibrium With […]

  • PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer

    What You Should Know: – PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. – PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and […]

  • Another big AI deal as Sanofi taps Exscientia for 15 new drugs

    If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery. Shortly after Amgen unveiled its $1.9 billion alliance with Generate Biomedicines aimed initially at five drug molecules, Sanofi has announced a big expansion of […]

  • Amgen pledges $1.9bn to alliance with AI specialist Generate

    Fresh from a sizeable funding round that raised $370 million, artificial intelligence-based drug discovery firm Generate Biomedicines has just signed its first major partnering deal with Amgen. The machine learning specialist – founded by venture capital firm Flagship Pioneering in 2018 – is getting $50 million upfront to kick off the alliance, with another £370 […]

  • Protai Nabs $8M for AI-Powered Drug Discovery Platform

    What You Should Know: – Protai, a Tel Aviv, Israel-based AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech. – Protai empowers drug discovery with proteomics and artificial intelligence to unlock new layers of biological insights and to combat […]

  • AI specialist Recursion nabs multibillion-dollar Roche partnership

    Roche has formed a decade-long alliance with Recursion Pharma that will focus on using machine learning and “industrialised” drug discovery to find new neuroscience and cancer drugs. The Swiss drugmaker is paying $150 million upfront to kick off the strategic-level partnership, which could cover as many as 40 programmes and could be worth “several billion […]

  • AWS and Pfizer Accelerate Drug Development and Clinical Manufacturing

    What You Should Know: Amazon Web Services (AWS) announced it is working with Pfizer to create innovative, cloud-based solutions to accelerate drug development and clinical manufacturing for testing in clinical trials. Today, Amazon Web Services, Inc. (AWS) announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how […]

  • GSK pumps £30m into a new Oxford University partnership

    GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the discovery of new medicines. The Oxford-GSK Institute of Molecular and Computational Medicine – based at Oxford’s Nuffield Department of Medicine – is being set up with £30 million (around $40 […]

  • Chinese tech giant Baidu licenses mRNA algorithm to Sanofi

    Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. The French drugmaker has been enticed by an artificial intelligence (AI) algorithm developed by Chinese tech giant Baidu, which controls most of China’s search engine traffic and is sometimes referred […]

  • Novo Nordisk on seeking partnerships to expand its portfolio

    Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’s senior VP of global drug discovery Karin Conde-Knape. She discusses which therapeutic areas the company is gaining momentum in and how it aims to build its presence […]

  • AI specialist Owkin snares $270m alliance with Sanofi in oncology

    Sanofi has made another investment in artificial intelligence, taking a $180 million equity stake in Franco-US startup Owkin with another $90 million in funding for a program to seek out new cancer therapies. The three-year project will focus on four types of cancer, and will deploy Owkin’s predictive biomedical AI models to find new biomarkers […]

  • Alphabet’s DeepMind forms AI drug discovery unit Isomorphic Labs

    Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into DeepMind’s AI-powered AlphaFold engine that last year became the first to solve the tricky problem of predicting protein folding, but will operate separately. It […]

  • Bionano frames $90M BioDiscovery buy as way to expand genomics analysis

    Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal. While both companies provide genomics analysis solutions, Bionano said combining its technology with BioDiscovery’s software will provide the integrated offering that many labs want.

  • AI specialist Exscientia raises $510m in upsized IPO, placing

    Exscientia’s artificial intelligence-based drug discovery engine is still largely unproven, but that hasn’t stopped the company raking in funding from investors keen to back its platform. The final numbers are now in from its recently announced initial public offering on the US Nasdaq, and the numbers are impressive, swelling from an initially forecast $304 million […]

  • Open Source “Wikipedia” for Drug Discovery

    By Kambiz Shekdar, Ph.D. Open source drug discovery was proposed in the past in connection with third-world diseases like tuberculosis and malaria, but it is in the context of first-world indications where it is needed most. Despite untold investment by numerous pharmaceutical companies, FDA-approved drugs that target critical brain functions and conditions like anxiety, depression, […]

  • 3rd Inflammasome Therapeutics Summit

    Discover the Intricacies of Inflammasome Regulation, Leverage Inflammasome Proteins as Biomarkers & Accelerate Novel Inflammasome Therapeutics into Proof-Of-Concept Clinical Trials & Beyond Built with Ventus Therapeutics, Inflammasome Therapeutics, Merck & more, the Inflammasome Therapeutics Summit returns for its third year as the only industry-dedicated forum to discover the intricacies of inflammasome regulation and accelerate novel […]

  • Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research

    Danish drugmaker Lundbeck has teamed up with Inscopix – the developer of a technology that can film neurons in the brain in real time – to try to find new drugs for central nervous system diseases. The two partners will use the nVista wearable microscope technology to develop a map of the brain and brain […]

  • A biotech startup’s hunt for elusive disease targets scores $60M for drug R&D

    Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to stand apart with its focus on understanding metabolic interactions, a path less trodden by others in allosteric drug discovery.

  • BMS buys into AI-designed immune drug from Exscientia

    Bristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Exscientia, paying $20 million for the buy-in as part of their $1.2 billion alliance. The unnamed drug candidate acts on an immunological kinase enzyme, which has proven hard to target using conventional drug discovery techniques because challenges […]

  • AI firm XtalPi swells its coffers with another $400m financing

    Artificial intelligence (AI) specialist XtalPi has chalked up a second big financing in the space of a year, raising $400 million and taking its valuation to around $2 billion. Founded several years ago by a team of MIT researchers and previously backed by Google, XtalPi deploys AI to a range of drug discovery and development […]

  • Bayer bolsters R&D platform with $2bn Vividion takeover

    Bayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will boost its ability to develop medicines against targets once considered “undruggable.” Bayer is paying $1.5 billion upfront to claim ownership of Vividion‘s drug discovery platform, which uses chemoproteomics to identify new binding sites on proteins and find […]

  • Google’s DeepMind puts human proteome online for free

    The most complete database of protein structures ever assembled, developed with the help of Google’s artificial intelligence unit DeepMind, has been made freely available to researchers around the world. DeepMind partnered with the European Molecular Biology Laboratory (EMBL) to come up with the AlphaFold database, which predicts the three-dimensional structures of the human proteome – […]

  • Gates Foundation backs COVID R&D at AI firm Exscientia

    Artificial intelligence-based drug discovery company Exscientia is stepping up its search for new COVID-19 medicines, thanks to an award by the Bill & Melinda Gates Foundation.  The $1.5 million grant will be used to develop a new class of small-molecule inhibitors of Mpro , a protease enzyme essential for the replication of the SARS-CoV-2 virus. […]

  • 4 Notable Life Sciences Trends from the Tech Trends Report

    The Future Today Institute has released its 2021 Tech Trends Report (14th Annual Edition), a comprehensive report on strategic trends that it anticipates will affect business, government, education, media and society in the coming year. We noted four trends discussed in the report’s Health, Medicine & Science section that will be of particular interest to […]

  • BMS embraces AI drug discovery with $1.2bn Exscientia alliance

    Exscientia has signed up another big pharma partner for its artificial intelligence (AI) based drug discovery platform, this time attracting a $50 million upfront buy-in from Bristol-Myers Squibb.  BMS wants to harness Exscientia’s tech to discover small-molecule drugs across a range of therapeutic categories – including immunology and oncology – and is promising another $125 […]

  • Exscientia starts trials of AI-designed Alzheimer’s drug

    Exscientia has advanced a drug candidate for Alzheimer’s disease into human testing, the third clinical-stage project for the UK specialist in artificial intelligence (AI) based drug discovery.  The new molecule – called DSP-0038 – is being developed by Japan’s Sumitomo Dainippon Pharma (DSP), which is now starting a phase 1 trial in the US as […]

  • InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

    Shots: InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, optimize novel targets with Shionogi’s expertise in developing and commercializing therapeutic modalities Shionogi will synthesize targets identified by InveniAI for certain strategic diseases and will […]

  • Here’s a look at natural product drug discovery 2.0

    Plant-based drug discovery may be tens of thousands of years old, but in 2021, it feels exciting, rich, and full of potential. Companies are rapidly building scalable databases with hundreds of thousands of unique chemicals and their links to biological signatures.

  • Q1 2021 Health IT/Digital Health PC/VE, M&A, IPOs/ SPACs Activity

    The first quarter of 2021 has been one of investor optimism as the vaccine rollout continues ahead of expectations and economic activity begins to accelerate in response.  Within the Health IT industry, the already strong investment and M&A trends seen in 2020 have only accelerated.  Over the course of the quarter, we observed $7 billion in private […]

  • Exscientia starts trials of first AI-derived cancer immunotherapy

    Exscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) last year, and now says it has started testing of the first AI candidate for immuno-oncology.  Oxford, UK-based Exscientia has been working with German biotech Evotec on the adenosine A2a receptor antagonist, which is being tested as […]

  • AI drug discovery player 1910 Genetics debuts with $26m war chest

    There’s a new kid on the block among companies using artificial intelligence in drug discovery, after 1910 Genetics launched today with $26 million in financing. The Cambridge, Massachusetts-based startup claims it is the only biotech launched so far that will use AI to design both small-molecule drugs and protein therapeutics, coupled with automated biological testing […]

  • Takeda Collaborates with Evotec on RNA Targeting Drug Development

    Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration The collaboration will utilize Evotec’s RNA targeting platform to identify RNA sequences to target with small-molecule ligands aligned that can be developed into the first-in-class […]

  • Welsh startup Antiverse raises $2m for antibody discovery toolkit

    New biotech Antiverse has raised seed funding of £1.4 million ($2 million) to develop its artificial intelligence-based platform for discovering therapeutic antibodies. The Cardiff, Wales startup is combining machine learning and phage display techniques to model antibody-antigen binding and says it can cut the time it takes to develop a drug candidate. It’s one of […]

  • AI drug discovery firm Valence joins Parkinson’s disease push

    Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkinson’s disease.  The go-to treatment for the five million people worldwide with Parkinson’s is levodopa, which replaces the activity of the dopamine neurotransmitter dopamine that gets depleted by […]

  • Exscientia Secures $100M To Expand AI Drug Discovery Platform

    What You Should Know: – Exscientia, leading AI drug discovery company, today announced that it completed its $100 million Series C financing round, with a further $30 million investment from Blackrock. – This new capital, which will be used to support Exscientia’s platform development and proprietary pipeline, follows Exscientia’s demonstrated high growth, having announced earlier this year […]

  • UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

    Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19 Microsoft will provide AI technology and applied scientists to work […]

  • Microsoft, UCB Launch Collaboration to Accelerate Drug Discovery and Development

    What You Should Know: – Global biopharma company UCB and Microsoft announced today a new, multi-year strategic collaboration to advance UCB’s digital transformation, change the way care is delivered, and accelerate better outcomes for people living with severe diseases. – The partnership builds on the companies’ joint work as part of the COVID Moonshot project which sought to create […]

  • Alzheimer’s Research UK starts AI-based drug hunt with Exscientia

    Medical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments for the devastating neurodegenerative disease.  The alliance will see Exscientia work with the charity’s Oxford Drug Discovery Institute (ODDI) to find therapeutics that target the neuroinflammation associated with Alzheimer’s disease (AD), focusing in particular on the NLRP3 […]

  • Evotec Collaborates with Related Sciences for Drug Discovery and Development

    Shots: Evotec to receive milestones, royalties, and a founding equity stake in all Related Sciences assets developed under the collaboration Evotec and Related Sciences will jointly discover & develop a multitude of therapeutic approaches with IND filings over a multi-year period. The partnership will combine Related Sciences’ collaborative model and data-driven approach to identify biological […]

  • Advancing Healthcare Delivery via Artificial Intelligence

    Artificial Intelligence have demonstrated intelligent behavior through their ability to learn, communicate with its users and solve complex problems using highly sophisticated algorithms. AI-driven technologies have continued to evolve rapidly, with several industries increasingly deploying such solutions across key aspects of value chain. Furthermore, AI is also made with same idea of making tasks simpler […]

  • Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development

    Shots: CQC collaborates with Roche to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development The collaboration will employ CQC’s quantum chemistry platform ‘EUMEN’, to augment the Roche’s AD research efforts The multi-year collaboration will combine the expertise of both CQC and Roche to advance the application of quantum computing to pharmaceutical […]

  • Elsevier to Work with Heel for Mechanism-based Drug Action Discovery

    Elsevier, the data analytics business specialized in science and health, and Heel, a pharmaceutical company specialized in developing and manufacturing medicines made from natural ingredients, have recently completed a series of research projects with a focus on improving exploratory preclinical studies. “We at Heel are pioneers in the field of systems research and have a […]

  • 30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021

    As we close out the year, we asked several healthcare executives to share their predictions and trends for 2021. Kimberly Powell, Vice President & General Manager, NVIDIA Healthcare Federated Learning: The clinical community will increase their use of federated learning approaches to build robust AI models across various institutions, geographies, patient demographics, and medical scanners. The sensitivity and […]

  • AI drug discovery biotech AbCellera eyes record IPO

    AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The Vancouver, Canada-headquartered biotech – which has been bankrolled in part by billionaire entrepreneur and venture capitalist Peter Thiel – plans to offer 23 […]

  • How the rare disease community has developed fertile ground for progress

    Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. New models of drug development are fuelling life-changing advantages in the rare disease space, previously an economic no-go area for pharma and biotech companies. That was […]

  • BioNTech, InstaDeep plan joint lab for AI research

    BioNTech may be deeply ensconced in the latter stages of its bid to bring a COVID-19 vaccine to market, but it’s still pushing forward on other fronts, including a partnership with InstaDeep to deploy artificial intelligence and machine learning across its business. The two companies have been working together in this area since 2019, but […]

  • Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China

    Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jennifer Yang, Head, Lung Cancer Initiative China, Johnson & Johnson Back row (left to right): Alex Zhavoronkov, Founder & CEO, Insilico Medicine; Li […]

  • Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies

    What You Should Know: – Mission Bio launches industry’s first and only single-cell multi-omics platform, is announcing the launch of its most comprehensive instrument to-date, to save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six months faster. – Mission Bio’s Tapestri Platform, the first single-cell […]

  • BMS joins forces with insitro to develop neurodegenerative treatments

    insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).  Neurodegenerative disorders such as ALS and FTD are considered a challenging therapeutic area, with no disease modifying treatments available today. insitro uses machine-learning technology to discover novel drug […]

  • JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

    What You Should Know: – The U.S. government’s Joint Pathology Center, which houses the world’s largest human tissue repository, today announced that Proscia, a leading digital and AI pathology company, will provide end-to-end modernization of JPC’s pathology operations. – The multi-phase project will digitize the world’s largest human pathology specimen repository in order to enhance […]


    While the definition of real world evidence is still evolving, most proponents associate it with data that is derived from medical practice among heterogeneous sets of patients in the real world setting. It is the integration of data gathered from various sources, such as EHRs, medical charts, patient claims and billing activities, product and disease […]

  • Roche Collaborates with Genesis Therapeutics for AI-Driven Drug Discovery

    Shots: Genesis to receive an up front and is eligible to receive pre/ clinical and regulatory milestones along with royalties on sales of approved drugs emerges from the collaboration The collaboration leverages Genesis’ graph machine learning and drug discovery expertise to identify drug candidates for therapeutic targets across multiple disease areas Genesis has developed Dynamic […]

  • AI drug-discovery firm lands first partnership

    The deal with Roche subsidiary Genentech is likely not the last for Genesis Therapeutics, which is based on AI research undertaken at Stanford. Such partnerships are potentially lucrative for drug-discovery startups.

  • How DNA-encoded Libraries Boost Drug Discovery

    DNA-encoded libraries (DELs) have been gaining a lot of traction in hit finding and drug discovery in recent years. Regarded by some as a truly revolutionary advance in chemistry, a DEL is a mixture of millions of small molecules in which each molecule is conjugated to a DNA-oligomer that encodes its chemical structure. The mixture […]

  • 4 Areas Driving AI Adoption in Hospital Operations and Patient Safety

    Renee Yao, Global Healthcare AI Startups Lead at NVIDIA COVID-19 has put a tremendous burden on hospitals, and the clinicians, nurses, and medical staff who make them run.  Many hospitals have suffered financially as they did not anticipate the severity of the disease. The extended duration of patient stays in ICUs, the need for more […]

  • Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics

    What You Should Know: – Repurpose.AI, has partnered with Scripps Research to discover drug candidates that may be repurposed to treat COVID-19.  – The partnership will leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover drug candidates to treat COVID-19.  Scripps Research is teaming up […]

  • Targeted Protein Degradation – Defining a New Frontier in the Field of Medicine

    The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, address fewer than 20% of the proteome, targeted protein degradation offers a unique means to tap into the rest of the […]

  • In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules

    Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has been witnessed. In addition to the complexities involved, the […]